1. Home
  2. CBL vs MNMD Comparison

CBL vs MNMD Comparison

Compare CBL & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CBL
  • MNMD
  • Stock Information
  • Founded
  • CBL 1978
  • MNMD 2019
  • Country
  • CBL United States
  • MNMD United States
  • Employees
  • CBL N/A
  • MNMD N/A
  • Industry
  • CBL Real Estate Investment Trusts
  • MNMD Pharmaceuticals and Biotechnology
  • Sector
  • CBL Real Estate
  • MNMD Health Care
  • Exchange
  • CBL Nasdaq
  • MNMD Nasdaq
  • Market Cap
  • CBL 898.9M
  • MNMD 960.2M
  • IPO Year
  • CBL 1993
  • MNMD N/A
  • Fundamental
  • Price
  • CBL $29.67
  • MNMD $12.41
  • Analyst Decision
  • CBL
  • MNMD Strong Buy
  • Analyst Count
  • CBL 0
  • MNMD 7
  • Target Price
  • CBL N/A
  • MNMD $26.71
  • AVG Volume (30 Days)
  • CBL 104.5K
  • MNMD 2.1M
  • Earning Date
  • CBL 11-10-2025
  • MNMD 10-31-2025
  • Dividend Yield
  • CBL 6.08%
  • MNMD N/A
  • EPS Growth
  • CBL 128.05
  • MNMD N/A
  • EPS
  • CBL 2.10
  • MNMD N/A
  • Revenue
  • CBL $539,452,000.00
  • MNMD N/A
  • Revenue This Year
  • CBL N/A
  • MNMD N/A
  • Revenue Next Year
  • CBL N/A
  • MNMD N/A
  • P/E Ratio
  • CBL $14.13
  • MNMD N/A
  • Revenue Growth
  • CBL 2.20
  • MNMD N/A
  • 52 Week Low
  • CBL $21.10
  • MNMD $4.70
  • 52 Week High
  • CBL $33.54
  • MNMD $14.30
  • Technical
  • Relative Strength Index (RSI)
  • CBL 49.67
  • MNMD 55.54
  • Support Level
  • CBL $28.86
  • MNMD $11.88
  • Resistance Level
  • CBL $29.90
  • MNMD $12.76
  • Average True Range (ATR)
  • CBL 0.58
  • MNMD 0.89
  • MACD
  • CBL 0.10
  • MNMD -0.10
  • Stochastic Oscillator
  • CBL 87.56
  • MNMD 31.02

About CBL CBL & Associates Properties Inc.

CBL & Associates Properties Inc is a real estate investment trust. The company engages in the ownership, development, acquisition, leasing, management and operation of regional shopping malls, outlet centers, lifestyle centers, open-air centers and other properties. CBL's sales predominantly derive from leasing arrangements with retail tenants. The company also generates revenue from management and development fees, as well as sales of its real estate assets. CBL expands its portfolio of assets through activities such as redevelopment, renovation, and expansion.

About MNMD Mind Medicine (MindMed) Inc.

Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).

Share on Social Networks: